Reduced endogenous secretory receptor for advanced glycation end products (esRAGE) in young XXXX with @entity1723 developing microalbuminuria.

@entity1 @entity2704 @entity1723 @entity6
AIMS: The endogenous secretory receptor for advanced glycation end products (esRAGE) appears to work as a scavenger for AGEs and it has been implicated in the pathogenesis of @entity6 complications. The aim of the present study was to perform a longitudinal evaluation of esRAGE in young @entity1 with @entity1723 ( @entity1723 ) in relation to the development of microalbuminuria ( @entity2704 ). METHODS: Serum esRAGE levels were measured in longitudinally collected blood samples from 49 @entity1723 @entity1 with @entity2704 ( @entity2704 +) and 49 matched normoalbuminuric @entity1 ( @entity2704 -), followed in the Oxford Regional Prospective Study. esRAGE levels were compared between @entity2704 + and @entity2704 - subjects in relation to the time of @entity2704 onset. RESULTS: Overall, esRAGE levels were significantly lower in @entity2704 + than in @entity2704 - subjects (0.727 +/- 0.396 vs. 0.936 +/- 0.433 ng/ml; P = 0.015). These differences between the two groups were present both before (0.725 +/- 0.410 vs. 0.956 +/- 0.505 ng/ml, P = 0.038) and after the onset of @entity2704 (0.750 +/- 0.433 vs. 0.948 +/- 0.418 ng/ml, P = 0.04). In a longitudinal analysis there was no effect of age, duration, glycated haemoglobin (HbA(1c)) or body mass index standard deviation scores on esRAGE levels (all P > 0.05). In a Cox model, esRAGE levels significantly contributed to the probability of developing @entity2704 [Exp(B)(95% confidence interval): 0.34(0.12-0.98); P = 0.04), independently of HbA(1c). CONCLUSIONS: In this longitudinal study of young @entity1 with @entity1723 , esRAGE levels were reduced in @entity2704 + subjects, even before the onset of @entity2704 , and appeared to be related to its development, thus suggesting a potential role of esRAGE in the pathogenesis of this complication. Diabet. Med. 26, 815-819 (2009).
